A Clinical and Preliminary Study for Anti-angiogenesis Therapy: Endostatin, VEGF and Microvessel Density in the OSCC in Different Stages and Differentiations

Main Article Content

Hong He
Jiaqin Wang
Xiaotong Deng
Danping Zhao

Abstract

Aims: This study was to analyze the association among ES, VEGF, Microvessel Density (MVD), clinicopathologic characteristics, angiogenesis and prognosis of OSCC.

Methods: Eight normal samples of oral epithelia and 52 Oral Squamous Cell Carcinoma (OSCC) samples were analyzed by immunohistochemical evaluation to study the expression and significance of Endostatin (ES) and Vascular Endothelial Growth Factor (VEGF) during the development of OSCC.

Results: Statistically significant differences were found as p<0.05 between VEGF expressions and clinicopathologic stages of OSCC and as p<0.01 between VEGF expressions and lymph node metastases of OSCC. And Statistically significant discrepancy was also found as p<0.05 between MVD and differentiation degrees and lymphnode metastases of OSCC, as well as p<0.01 between VEGF expressions and MVD. Additionally MVD increased gradually in accordance with the progression of the Cancer. While there was no obvious correlation between ES and VEGF, ES and MVD, as well as between ES and the development of OSCC.

Conclusion: By MVD et al evaluation, VEGF is one of the major angiogenesis factors for angiogenesis and lymphonode metastasis of oral carcinomas, as an important indicator for the development and malignancy of OSCC, while ES is of significance for anti-angiogenesis in tumor therapy.

Keywords:
Endostatin, vascular endothelial growth factor, microvessel density, OSCC, immunohistochemistry.

Article Details

How to Cite
He, H., Wang, J., Deng, X., & Zhao, D. (2020). A Clinical and Preliminary Study for Anti-angiogenesis Therapy: Endostatin, VEGF and Microvessel Density in the OSCC in Different Stages and Differentiations. Journal of Advances in Medicine and Medical Research, 32(1), 71-79. https://doi.org/10.9734/jammr/2020/v32i130351
Section
Original Research Article

References

Johnstone S, Logan RM. The role of Vascular Endothelial Growth Factor (VEGF) inoral dysplasia and oral squamous cell carcinoma. [J]. Oral. Oncol. 2006;42(4): 337-342.

Cai Y, Zeng J, Chen S, Fan Y. Expression of vascular endothelial growth factor in oral lichen planus and squamous cell carcinoma. Beijing. J. Stomatol. 2010;18(2): 84-86.

Kapoor P, Deshmukh R. VEGF: A critical driver for angiogenesis and subsequent tumor growth: An IHC study. J. Oral. Maxillofac. Pathol. 2012;16(3):330-337.

Shibuya M. Vascular Endothelial Growth Factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti and pro-angiogenic therapies. Genes. Cancer. 2011;2(12):1097-105.

Shibuya M. Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases. Journal of Biochemistry. 2013;153(1): 13–19.

Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140:460-476.

Melincovici CS, Boşca AB, Şuşman S, et al. Vascular Endothelial Growth Factor (VEGF) - Key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455-467.

Karaman S, Leppänen VM, Alitalo K. Development. Vascular endothelial growth factor signaling in development and disease. 2018;145(14).
DOI:10.1242/dev.151019

Folkman J. Antiangiogenesis in cancer therapy - Endostatin and its mechanisms of action. J. Experimental. Cell. Res. 2006; 312(5):594-607.

Walia A, Yang JF, Huang YH, et al. Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease and clinical applications. Biochimica et Biophysica Acta. 2015;1850(12):2422-2438.

Viallard C, Larrivée B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis. 2017; 20(4):409-426.

Hanahan D, Folkman J. Patterns and emerging mechanism of the angiogenic switch during tumorigenesis. J. Cell. 1995; 86:353-364.

Folkman J. What id the evidence that tumors are angiogenesis dependent? J. National. Ca. Insti. 1990;82(1):4-6.

Denhart BC, Guidi AJ, Tognazzi K, et al. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia. J. Lab. Invest. 1997;77(6):659-664.

Michailidou EZ, Markopoulos AK, Antoniades DZ. VEGF expression from human dysplastic or malignant oral epithelium may be related to mast cell density and the subsequent angiogenetic phenomena. Int. J. Oral. Maxillofac. Surg. 2012;41(12):1467-73.

O'Relly MS. Boelm T, Shing Y, Fukai N, et al. Endostatin: An endogeneous inhibitor of angiogenesis and tumor growth. J. Cell. 1997;88:277-285.

Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nat. 1997;390(6658):440-407.

Xu H, Niu X, Zhang Q, et al. Synergistic antitumor efficacy by combining adriamycin with recombinant human endostatin in an osteosarcoma model. Oncol. Lett. 2011;2 (5):773-778.

Zhang K, Wang Y, Yu X, et al. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth. BMC Cancer. 2017;17(1):899.